2ME2 suppresses plasmacytoma growth and increases survival in immune deficient beige-nude-xid (BNX) mice.
Mice were inoculated subcutaneously in the flank with 3 × 107 RPMI 8226 MM cells in 100 μL RPMI 1640 medium, together with 100 μL Matrigel. 2ME2 (100 mg/kg) was started after the development of measurable tumor and was given daily using an orogastric feeding tube; carboxymethylcellulose 0.5% served as a control. Serial caliper measurements of perpendicular diameters were taken every other day to calculate tumor volume (A). Each time point represents the mean ± SD of 10 mice. Survival of 2ME2 versus control animals (B). Frozen tumor samples were stained by anti–CD-31 antibody, and the vessels were counted and averaged in control (C) versus 2ME2-treated (D) animals. Arrows denote CD31+ blood vessels. (E) Significantly fewer CD31+ blood vessels were observed in 2ME2-treated than in control animals (P < .05).
